Home/Biosimilar Atlas/Ranibizumab/Sun Pharma ranibizumab

Sun Pharma ranibizumab

Ranibizumab biosimilar developed by Sun Pharmaceutical Industries. Reference product Lucentis.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Sun Pharma · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOMar 2023permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
RanibizumabmoleculeSun Pharmaceutical Industriesdeveloper1 of 7markets0trials behind it1other products, same developer5rival developers in its markets

About Sun Pharma ranibizumab

Sun Pharma received its ranibizumab permission in India in March 2023, with diabetic macular oedema and vein occlusion added in 2024. It is one of Sun's few biosimilars.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Sun Pharmaceutical Industries Limited
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Mar 2023
Application or permission
MF/BIO/23/000020; additional indications MF/BIO/24/000006
Indications as licensed
Wet AMD at permission; DME and RVO added January 2024
Presentations
10 mg/mL single-use vial
Source
S011 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Sun Pharma ranibizumab holds an approval, these are the other ranibizumab biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO5Enzene Biosciences (Enzene Biosciences ranibizumab), Intas Pharmaceuticals (Rexatilux / Razumab), Lupin (Ranluspec / Vislyfa), Reliance Life Sciences (Reliance Life Sciences ranibizumab), Zenotech Laboratories (Zenotech ranibizumab)

Same developer, other molecules

Other biosimilars in the Atlas developed by Sun Pharmaceutical Industries: Teriparatide Sun.

Chronology

Sources

All ranibizumab biosimilars

Planning ranibizumab biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.